SVP at Lonza Group AG
- Salient developments in the C> (cell and gene therapy) manufacturing market, including outsourcing rate, manufacturing economics and supply chain pressures
- Latest M&A, corporate strategy and CAPEX trends among key tier 1 C> CDMO (contract development and manufacturing organisation) incumbents
- Lonza’s (VTX: LONN) competitive landscape, strengths and weaknesses
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.